Mindset Pharma Inc. announced that the United States Patent and Trademark Office (“USPTO”) has granted allowance for another of Mindset's Family 1 patent applications, number 17/743,718, titled “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.” Included in this patent are certain deuterated psilocybin analogs from Family 1. Family 1 consists of psilocybin-inspired drug candidates that demonstrate improved pharmacokinetic, efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement, in pre-clinical studies. This application is one of a family of applications having a priority date of February 4, 2020.